Year: 2017
Language: English
Author(s): Albert Farrugia
Format: Document
The purpose of this guide is to inform and facilitate the selection and purchase of therapeutic products for the treatment of hemophilia.
It discusses the factors that contribute to the quality, safety, and efficacy of hemophilia treatment products and, in particular, the provisions made for ensuring that these products are free of viruses. It covers well-established systems in the United States and the European Union that regulate and control therapeutic products for hemophilia.
For regulatory agencies in countries without established systems, this guide provides guidance for the development of procedures, and offers a model for the evaluation of products, to ensure the safety and quality of therapeutic products for hemophilia.
Listen to this 90-minute webinar presented on March 8, 2022, to learn about women and girls with bleeding disorders. The
In this session from the WFH 2020 Virtual Summit, Assad Haffar, Megan Adediran, Kibet Shikuku, Glenn Pierce, Alain Baumann, Bill
In this session from the WFH 2020 Virtual Summit, Deon York, Nathalie Roussel, Cathy Harrison, Lauren Phillips & Randall Curtis
In this plenary from the WFH 2020 Virtual Summit, Kate Khair, Michelle Lavin, Rezan Abdul-Kadir & Jameela Sathar will address
In this session from the WFH 2020 Virtual Summit, Glenn Pierce, Johnny Mahlangu, David Page & Brian O’Mahony explore the
In this session from the WFH 2020 Virtual Summit, Radoslaw Kaczmarek, Flora Peyvandi, Dan Hart & Johnny Mahlangu discuss novel